Marshall may be an incompetent CEO but he is not dumb.
He has been able to keep the the company financed and a nice paycheck coming in for many years.
Despite the many blunders he has made the backers keep him living in style.
So what is our backers game?
One can only speculate, but you can bet they're satisfied with Marshall or he wouldn't be there and probably Medizone would not be there either.
They have had ample opportunities over the years to flip enough shares to recoup their investments and make a nice profit along the way.
Every time Marshall goes back to the well he can be depended on to come up with some timely hype to get the share price up enough for our investors to make their move.
However, at this point, I don't think the old game is going to work anymore. ASure is no longer a new product, it's been around now for over two years without a single sale, service contract or hospital trial and no EPA approval. In the meantime, competitive products are taking off and Medizone isn't even in the picture.
Why?
I think it's more than just Marshall's lack of executive ability and EPA approval. I think there is resistance to ASure in the market for any number of possible reasons.
It appears to me Asure's pitch of 99.9999 clean isn't cutting it.
They are up against quick and easy alternatives that are demonstrating they can reduce infections... all anybody cares about.
ASure is cumbersome and time consuming and using ozone which has a bad rap in the medical community. Medizone is depending on their extra 99 log numbers to carry the day. As competitive devices gain wider and wider acceptance and proof of effectiveness, it is becoming evident those extra 9's aren't as necessary as anticipated to get the job done and not worth the hassle and time to use ASure.
There is probably a niche in the marketplace for ASure but not the mainstream one everyone was hoping for. In outbreak situations where it's important to get every last bug Asure has a place. Beyond that, Medizone has an impossible uphill battle in the hospital market.
They're going to have to rethink their strategy if the company is to survive.
